| Patent application number | Description | Published |
|---|
| 20080260762 | HLA binding motifs and peptides and their uses - The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. | 10-23-2008 |
| 20080274129 | Hla-A2 Tumor Associated Antigen Peptides and Compositions - A peptide or composition comprising at least one HLA-A2 epitope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53. | 11-06-2008 |
| 20080279924 | HLA class I A2 tumor associated antigen peptides and vaccine compositions - A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2/neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6. | 11-13-2008 |
| 20090012004 | HLA binding peptides and their uses - The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, | 01-08-2009 |
| 20090169574 | Heteroclitic analogs and related methods - Heteroclitic analogs of Class I epitopes are prepared by providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wildtype epitopes. | 07-02-2009 |
| 20090214632 | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HPV infection. | 08-27-2009 |
| 20090304746 | Inducing cellar immune responses to hepatitis C virus using peptide and nucleic acid compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare HCV epitopes, and to develop epitope-based vaccines directed towards HCV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HCV infection. | 12-10-2009 |
| 20090311283 | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection. | 12-17-2009 |
| 20090317412 | Induction of an immune response against streptococcus pneumoniae polyaccharides - The present invention provides conjugates of pan DR binding peptides with | 12-24-2009 |
| 20100049491 | Method and System for Optimizing Minigenes and Peptides Encoded Thereby - The invention relates to the field of biology. In particular, the invention relates to a method and system for designing optimized multi-epitope vaccines having selected combinations of amino acid insertions at the junctions of the multi-epitope constructs so as to minimize the number of junctional epitopes and provide vaccines with increased immunogenicity. | 02-25-2010 |
| 20100068218 | Optimized Multi-Epitope Constructs and Uses Thereof - The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity. | 03-18-2010 |
| 20100068228 | Inducing Cellular Immune Responses to Hepatitis B Virus Using Peptide and Nucleic Acid Compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection. | 03-18-2010 |
| 20100209493 | HLA-A2 Tumor Associated Antigen Peptides and Compositions - A peptide or composition comprising at least one HLA-A2 epi tope or analog from CEA, HER2/neu, MAGE2, MAGE3, or p53. | 08-19-2010 |
| 20110097352 | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection. | 04-28-2011 |
| 20110150914 | COMPOSITIONS AND METHODS FOR DENGUE VIRUS (DV) TREATMENT AND VACCINATION - The invention relates to Dengue virus (DV) peptides and compositions thereof, and methods that employ Dengue virus (DV) peptides and compositions thereof. The invention includes among other things, methods of treating Dengue virus (DV) infection or pathology, which include, for example, administering Dengue virus (DV) peptide T cell epitope, to treat a Dengue virus (DV) infection or pathology. The invention includes among other things Dengue virus (DV) vaccination and immunization methods. | 06-23-2011 |
